DRL in agreement with AstraZeneca Pharma India for Riax and Riax M

DRL will be distributing Riax and Riax M in India

Dr Reddy’s Laboratories (DRL) and AstraZeneca Pharma India have entered into a distribution agreement for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group.

AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and distributed in the Indian market. Onglyza (saxagliptin), AstraZeneca’s patented therapy, is an oral hypoglycemic (anti-diabetic therapy) in the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus in multiple clinical settings.

DRL will be distributing Riax and Riax M in India. This partnership strengthens DRL’s diabetes franchise in India. It enables AstraZeneca to expand usage of this molecule through wider reach to physicians and benefiting more number of diabetic patients.